Grünenthal developed novel resiniferatoxin (RTX), for the pain associated with osteoarthritis (OA) of the knee which is currently undergoing clinical Phase III development.
Resiniferatoxin, is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. By administering it as an intra-articular injection directly into the knee joint, it aims to defunctionalise TRPV1-expressing nociceptors, providing long-lasting pain relief for patients with knee osteoarthritis. Preliminary data showed a significant analgesic effect and functional improvement compared to placebo with a favourable safety profile.
Millions of patients suffering from knee osteoarthritis eagerly await additional treatment options, as the disease currently lacks a cure. Resiniferatoxin holds promise as a potential solution to alleviate the pain associated with this condition.
Resiniferatoxin, if granted approval, holds promising potential as a non-opioid treatment option that can offer enduring pain relief and enhance the functioning of the affected joint. Additionally, it demonstrates a favourable safety profile, further adding to its value as a viable treatment alternative.
U.S. Food and Drug Administration (FDA) grants breakthrough designation for resiniferatoxin for the treatment of pain associated with knee osteoarthritis.
